MD Integrations Review (2026): The Physician-Only API, Examined

What MD Integrations is, precisely

Its own framing: the only white-label telemedicine platform powered exclusively by physicians, with 'you control the brand, we power the medicine' as the division of labor. Concretely that is an API-first clinical layer: asynchronous visits reviewed by board-certified physicians, prescription routing to pharmacies, webhooks and documentation aimed at engineering teams, and stated coverage across all 50 states plus DC and Guam, across twelve-plus specialties. Its marketing leans on integration speed, with roughly a week of integration work as the recurring claim.

The physician-only claim is a real differentiator to understand rather than a slogan: most networks in this category staff with a mix of physicians and NPs or PAs, and MDI's stated model excludes the mid-level layer entirely. Whether that matters to your program is a clinical-governance and cost question (physician review on every case, at physician economics), not a quality verdict either way; ask how it prices through to your per-visit cost. It also ships commerce-adjacent rails the category mostly lacks: a Shopify app and a WooCommerce plugin, per its own listings.

The 2026 diligence items

Pricing is quoted, not published, as of September 2026: expect visit-volume-shaped pricing for the API, with everything around the visit (storefront, pharmacy economics, growth stack) remaining your build and your cost. The company took significant capital in October 2025: a $77M investment from Updata Partners and Denali Growth Partners, announced alongside appointing a president and COO. Capitalization plus fresh leadership are both reference-call material: ask what changed for customers your size after the raise, on the roadmap and on pricing.

Third-party review coverage on the B2B marketplaces is thin, as it is across this category, so diligence runs through documentation review and references. The specific references worth asking for: teams that integrated in the last year (how long it really took against the roughly-a-week marketing claim), and teams running your care lines (how the physician-only model performs on turnaround and cost at your volume). Our reference-call script guide has the full question set.

The three questions that decide an MDI evaluation: the all-in per-visit cost at your volume once physician-only review is priced in, in writing; how long integration actually took the last three customers your size; and who owns the pharmacy economics on the prescriptions its API routes.

Who it fits, and who should look elsewhere

Good fit: developer-led teams that want a focused asynchronous clinical layer behind a stack they own, value documentation quality, and have a clinical reason (or a positioning reason) to prefer physician-only review. In that lane its closest comparison is Beluga Health (broader end-to-end scope, physician-led, sync and async), and the choice usually turns on scope: MDI for a clean visit-and-routing API, Beluga when you want fulfillment routing under the same roof; our head-to-head page walks it dimension by dimension.

Look elsewhere if you need synchronous care as a first-class mode (MDI's public positioning is async-first; verify current sync support directly if your care lines need video), or if the parts you actually need solved are the storefront, funnel, retention, and medication economics, which the API model leaves to you by design.

Where EmbedCare sits, since we brought it up

EmbedCare is the operated alternative: instead of an API you build against, the storefront, 50-state clinicians, owned pharmacy supply, retention, and compliance run behind your brand on flat product rates fixed in a signed partner agreement, with medication included on GLP-1 programs and a self-serve Launch tier starting at $495/mo. If your team's scarce resource is engineering time rather than audience, that is the comparison to run, and our MD Integrations comparison page walks it dimension by dimension.